ArticleArchives of microbiology2026
Recombinant Amuc_1100 from Akkermansia muciniphila modulates tight junction-associated protein in vaginal epithelial cells.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Amuc_1100, an outer membrane protein of the mucin-degrading commensal bacterium Akkermansia muciniphila, is known to strengthen intestinal epithelial barrier integrity, with reports suggesting a potential involvement of Toll-like receptor 2 (TLR2). Its role in the vaginal epithelial barrier, however, remains unexplored. In this study, recombinant Amuc_1100 was expressed in a baculovirus-insect cell system and purified by immobilized metal affinity chromatography (IMAC). Purified Amuc_1100 exhibited concentration-dependent binding to recombinant TLR2 in ELISA. In VK2/E6E7 vaginal epithelial cells, Amuc_1100 treatment did not alter viability across the tested concentrations, confirming the absence of cytotoxicity. Western blot analysis demonstrated that Amuc_1100 treatment significantly increased the expression of tight junction-associated proteins, including Zonula Occludens-1 (ZO-1), Claudin-1 (CLDN-1), and Claudin-4 (CLDN-4), under basal conditions. Furthermore, stimulation with lipopolysaccharide (LPS) or zymosan A markedly reduced ZO-1 levels, whereas co-treatment with Amuc_1100 restored expression under both conditions. Collectively, these findings provide preliminary evidence that recombinant Amuc_1100 modulates tight junction-associated protein expression in vaginal epithelial cells. However, additional functional barrier assays, mechanistic studies, and in vivo validation are required to further evaluate its potential as a postbiotic candidate.
Indexed as
Identifiers
42554872What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.